Related Experiment Videos
Hypogammaglobulinemia during antipsychotic therapy
1Department of Psychiatry, Institute of Clinical Medicine, The University of Tsukuba, Japan.
Psychiatry and Clinical Neurosciences
|July 31, 1998
Summary
Antipsychotic medication chlorpromazine (CPZ) may cause hypogammaglobulinemia, a decrease in immunoglobulin levels. Switching to timiperone resolved the condition, suggesting CPZ inhibited immunoglobulin synthesis.
Area of Science:
- Immunology
- Psychiatry
- Pharmacology
Background:
- Brief psychotic disorder is a psychiatric condition.
- Antipsychotic medications are used to treat psychosis.
- Hypogammaglobulinemia is a condition characterized by low levels of immunoglobulins.
Observation:
- A 22-year-old woman with brief psychotic disorder developed hypogammaglobulinemia during antipsychotic therapy.
- Serum immunoglobulin IgM, IgG, and IgA levels significantly decreased after 4 months of chlorpromazine (CPZ) and other antipsychotic treatment.
- No underlying physical diseases or family history of immunological issues were identified.
Findings:
- The patient's hypogammaglobulinemia was linked to chlorpromazine (CPZ) treatment.
- Gammaglobulin levels normalized after discontinuing CPZ and switching to timiperone.
- CPZ was considered to inhibit immunoglobulin synthesis.
Implications:
- This case highlights a potential adverse effect of chlorpromazine (CPZ) on the immune system.
- Clinicians should monitor immunoglobulin levels in patients on long-term antipsychotic therapy.
- Further research is needed to understand the mechanism of CPZ-induced hypogammaglobulinemia.